Insights about U.S. Stocks that landed in the Red-Zone during Tuesday’s trade, are depicted underneath:
MannKind Corporation (NASDAQ:MNKD)’s shares dwindled - 7.23%, and closed at $6.16, during the last trading session.
MannKind Corp. (MNKD), formerly on February 24, stated financial results for the fourth quarter and full year ended December 31, 2014.
For the fourth quarter, our operating expenses declined 35% contrast to the similar quarter in 2013. Research and development costs were significantly lower, mainly due to a reduction in non-cash compensation expenses and much lower clinical trial expenses following the completion of the Affinity studies in 2013. General and administrative costs declined 29%, mainly reflecting lower non-cash compensation expenses.
For the full year 2014, our total operating expenses raised modestly, with a decrease in research and development costs offset by an raise in general and administrative costs. Research and development costs reduced due to the completion of our Affinity trials, the pivotal clinical trials regarding the efficacy and safety of our novel inhaled insulin, Afrezza. Higher general and administrative costs resulted primarily from raised professional fees, principally related to the negotiation and completion of a partnership contract with Sanofi. In addition, professional fees reflected a noteworthy expansion in our program to identify, screen and fully evaluate new product opportunities that will best take advantage of the unique advantages of our Technosphere(R) drug delivery technology.
The net loss applicable to ordinary stockholders for 2014 was $198.4 million or $0.51 per share based on 385.2 million weighted average shares outstanding, slightly higher than the net loss to ordinary shareholders of $191.5 million, or $0.64 per share on 299.6 million weighted average shares outstanding in 2013. Our ordinary shares outstanding at year-end 2014 were 406.1 million.
Cash and cash equivalents at the end of 2014 were $120.8 million. Subsequent to year end, we received $50.0 million regarding two product development milestones achieved in the fourth quarter of 2014 from our partnership contract with Sanofi. In addition, we have $30.1 million of borrowings remaining under the loan arrangement with the Mann Group.
“After achieving a number of noteworthy milestones during 2014, we began the commercial production of Afrezza during the fourth quarter of the year,” said Hakan Edstrom, MannKind’s President and Chief Executive Officer. “With our flagship product, Afrezza(C), in the early stages of its commercial launch in the United States, we now enter a very exciting new phase for MannKind.”
MannKind Corporation, a biopharmaceutical corporation, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States. Its lead product candidate is AFREZZA inhalation powder, an insulin that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia.
TrueCar Inc (NASDAQ:TRUE), declined - 7.72%, and closed at $17.68. The stock volatility for the week is 6.69%, while for the month it is 6.58%. The company has the market capitalization of $1.54B. The mean recommendation of analysts for this stock is 2.30.(where 1=Buy, 5=Sale).
TrueCar, Inc. operates as an Internet-based information, technology, and communication services corporation. The corporation operates data-driven online platform through its TrueCar.com Website. TrueCar, Inc. also operates its platform for affinity group marketing partners, such as USAA and consumer reports, financial institutions, and other large enterprises.
Solazyme Inc (NASDAQ:SZYM), dipped -7.46%, and closed at $2.48.
Solazyme, Inc. (SZYM), a renewable oil and ingredients corporation, declared its participation in the Morgan Stanley MLP/Diversified Natural Gas, Utilities & Clean Tech Conference on March 5, 2015.
Tyler Painter, Chief Financial Officer and Chief Operating Officer, will be participating in one-on-one meetings with investors who are registered to attend the conference. Solazyme will not be giving a formal presentation.
Solazyme, Inc. (SZYM) is a leading microalgae innovator that delivers first-of-a-kind, high-performance oils and ingredients that are better for people and better for the planet. Starting with microalgae, the world’s original oil producer, Solazyme creates new, sustainable, high-performance products.
Allied Nevada Gold Corp. (NYSEMKT:ANV), dropped -7.29%, and closed at $0.862. The company has the market capitalization of $117.46M. The beta value of the stock is 0.18. On the other hand the stock’s volatility for the week is 8.09%, and for the month is 7.97%. The stock price to book value is $0.12, however price to sale value is $0.33. Analyst’s mean recommendation regarding this stock is 3.60. (where 1=Buy, 5=Sale).
Allied Nevada Gold Corp., a gold producer, is engaged in the mining, development, and exploration of properties in Nevada. The corporation’s principal products comprise unrefined gold and silver bars.
